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Nailfold Videocapillaroscopic Features and Other Clinical
Risk Factors for Digital Ulcers in Systemic Sclerosis
A Multicenter, Prospective Cohort Study
Maurizio Cutolo,1 Ariane L. Herrick,2 Oliver Distler,3 Mike O. Becker,4 Emma Beltran,5
Patrick Carpentier,6 Clodoveo Ferri,7 Murat Inanc¸,8 Panayiotis Vlachoyiannopoulos,9
Harbajan Chadha-Boreham,10 Emmanuelle Cottreel,10 Thomas Pfister,10 Daniel Rosenberg,10
Juan V. Torres,11 and Vanessa Smith,12 on behalf of the CAP Study Investigators
Objective. To identify nailfold videocapillaroscopic
features and other clinical risk factors for new digital
ulcers (DUs) during a 6-month period in patients with
systemic sclerosis (SSc).
Methods. In this multicenter, prospective, observa-
tional cohort study, the videoCAPillaroscopy (CAP) study,
we evaluated 623 patients with SSc from 59 centers (14
countries). Patients were stratified into 2 groups: a DU his-
tory group and a no DU history group. At enrollment,
patients underwent detailed nailfold videocapillaroscopic
evaluation and assessment of demographic characteristics,
DU status, and clinical and SSc characteristics. Risk factors
for developing new DUs were assessed using univariable
andmultivariable logistic regression (MLR) analyses.
Results. Of the 468 patients in the DU history
group (mean6SD age 54.06 13.7 years), 79.5% were
female, 59.8% had limited cutaneous SSc, and 22%
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developed a new DU during follow-up. The strongest risk
factors for new DUs identified by MLR in the DU history
group included the mean number of capillaries per milli-
meter in the middle finger of the dominant hand, the num-
ber of DUs (categorized as 0, 1, 2, or‡3), and the presence
of critical digital ischemia. The receiver operating charac-
teristic (ROC) of the area under the curve (AUC) of the
final MLRmodel was 0.738 (95% confidence interval [95%
CI] 0.681–0.795). Internal validation through bootstrap
generated a ROCAUC of 0.633 (95% CI 0.510–0.756).
Conclusion. This international prospective study,
which included detailed nailfold videocapillaroscopic eval-
uation and extensive clinical characterization of patients
with SSc, identified the mean number of capillaries per
millimeter in the middle finger of the dominant hand, the
number of DUs at enrollment, and the presence of critical
digital ischemia at enrollment as risk factors for the
development of new DUs.
Systemic sclerosis (SSc) is a rare multisystem
connective tissue disease characterized by microvascular
damage, fibrosis of the skin and internal organs, and
specific immunologic abnormalities. Digital ulceration,
which represents a visible manifestation of peripheral
vasculopathy, is a frequent complication of SSc, with an
estimated lifetime prevalence of as much as 50% (1,2).
Digital ulcers (DUs) often occur relatively early in
the course of the disease, causing severe pain and func-
tional impairment, and have a great impact on patients’
quality of life (3–11). DUs can also result in significant dis-
figurement and infection and may lead to gangrene, osteo-
myelitis, and eventually, amputation (4). Furthermore,
DUs are often persistent, recurrent, and slow to heal,
requiring considerable resources for wound management
and nursing care (2,12). Given the clinical and financial
burden, as well as the availability of therapies to prevent
DUs in patients with SSc (13), there is a need to identify
risk factors for the development of new DUs. In addition
to the established role of capillaroscopy in the diagnosis of
SSc (14–16) and the evaluation of its possible role in moni-
toring SSc, some studies have reported that abnormalities
noted on capillaroscopy are associated with DUs (17–25).
The aim of this study was to identify potential
risk factors for the occurrence of new DUs during a 6-
month period in patients with SSc, based on nailfold
videocapillaroscopy (NVC) findings and other clinical
characteristics.
PATIENTS AND METHODS
Study design. The videoCAPillaroscopy (CAP) study
was a multicenter, prospective, observational cohort study with
stratified enrollment into DU history and no DU history
groups. Potential risk factors for the development of DUs were
evaluated in the DU history group. The no DU history group
was included for exploratory purposes only, as the incidence of
new DUs was expected to be low. Enrollment occurred over a
1-year period to minimize seasonal effects. Patients were moni-
tored from the time of enrollment until the occurrence of a new
DU or a maximum of 6 months, whichever came first. At enroll-
ment, patients were provided with an educational leaflet on the
identification of DUs, and staff at each center telephoned
patients monthly to inquire about the occurrence of new DUs.
If a DU was reported, a patient visit was organized so that the
physician could confirm or exclude the presence of a DU.
Data management was performed centrally, and data
quality was rigorously monitored. Consistency of the source
data with the clinical database was verified for critical variables
for 3 randomly selected patients per site (or fewer, if fewer
patients had been enrolled). Data were reviewed regularly.
The CAP study was led by an independent steering
committee (see the Supplementary Materials, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.39718/abstract). The complete list of CAP
study investigators is also given in the Supplementary Materi-
als. This study was conducted in accordance with the Declara-
tion of Helsinki and its amendments, followed the Guidelines
for Good Clinical Practice of the International Conference on
Harmonisation, and was approved by the local institutional
review boards and ethics committees. All patients provided
written informed consent.
Study population. Fifty-nine SSc centers in 14 coun-
tries (12 European countries and Turkey and Israel) participated
in the study between January 31, 2011 and July 26, 2012. Patients
ages $18 years with a diagnosis of SSc according to the Ameri-
can College of Rheumatology (ACR) (26) and/or the LeRoy and
Medsger (14) criteria were eligible for inclusion. The inclusion
criteria were broad to permit generalizability to a wider SSc pop-
ulation. To enrich for the occurrence of new DUs in the study
population, the patients had to meet 1 of the following 2 criteria:
1) a history of DUs or a DU at enrollment (DU history group),
or 2) a disease duration of #2 years (no DU history group),
defined as the time since the first physician-documented non–
Raynaud’s phenomenon clinical feature of SSc (3).
As the study was conducted to allow for extrapolation of
the results to the real-world setting, patients were permitted to
continue their ongoing treatments. Patients unable to undergo
NVC assessment were not eligible for study inclusion. Patients
with SSc sine scleroderma were excluded as they were not
expected to develop DUs frequently during the 6-month observa-
tion period. Furthermore, patients who had undergone stem cell
transplantation or had participated in an interventional clinical
trial within 3 months prior to enrollment were excluded since
these interventions may have unknown effects on the occurrence
of new DUs.
Data collection. Covariables of demographic features,
SSc clinical characteristics, DUs, and other clinical characteris-
tics, as well as findings of the NVC were collected at enrollment
and are summarized in Table 1 and Supplementary Tables 1–4
(non-NVC covariables) and in Table 2 and Supplementary
Tables 5 and 6 (NVC covariables) (Supplementary Materials are
available online at http://onlinelibrary.wiley.com/doi/10.1002/art.
39718/abstract). Covariables of DU characteristics included a
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history of DUs (assessed at the investigator’s discretion), the
presence of DUs (number and location), and previous and cur-
rent DU-associated complications/interventions, including critical
digital ischemia (defined as a prolonged, severe, persistent reduc-
tion in digital tissue perfusion without rewarming [see Supple-
mentary Table 7 and Supplementary Figure 1]).
Information on medication use within 3 months prior
to enrollment, at enrollment, and during the observation
period was recorded as predefined classes of medications,
including vasoactive medications and immunosuppressants.
Study outcome. A DU was defined clinically as a
denuded area located on the fingers and with a defined border
and loss of epithelialization and a loss of epidermis and dermis.
The definition excluded fissures, paronychia, pitting scars, or
ulcers located over the metacarpophalangeal joints or elbows (see
Supplementary Table 7, available online at http://onlinelibrary.
wiley.com/doi/10.1002/art.39718/abstract). DUs distal to the meta-
carpophalangeal joint and on the volar and dorsal aspects of the
hand were included (see Supplementary Figure 1). Calcinosis-
induced ulcers were not specifically excluded.
A patient’s DU outcome was recorded as a binary vari-
able: either the occurrence or nonoccurrence of a new DU.
Cases were defined as patients who experienced a new DU
that was confirmed by the investigator during the 6-month
observation period. Noncases were defined as patients who
did not experience a new DU during the 6-month observation
period. For noncases, the nonoccurrence of a new DU was
recognized only if the patient had been contacted successfully
by staff for at least 3 of the monthly phone calls, including the
month 6 phone call, and had reported no new DUs or if the
noncases had reported a new DU that had not been confirmed
by the investigators. Physicians assessing the presence of DUs
were not blinded to the data collected at enrollment.
Collection and assessment of the NVC images. The
nailfolds of the second, third, fourth, and fifth fingers of both
hands were examined in each patient with the use of a
videocapillaroscope equipped with a 2003 magnification lens,
which is commonly used for NVC (5,27,28), and connected to
image analysis software. Two adjacent fields extending over 1 mm,
in the middle of the nailfold, and corresponding to the distal row
of capillaries were studied (27). Images were evaluated using qual-
itative and quantitative assessment techniques (18,27,29).
Qualitative assessment of images (1 covariable) (see Sup-
plementary Table 6) classified the patient as having the normal,
early, active, or late scleroderma NVC pattern according to
Cutolo et al (29) (see Supplementary Materials, Investigator
booklet, available online at http://onlinelibrary.wiley.com/doi/10.
1002/art.39718/abstract). Quantitative assessment of images (6
covariables in each of the 8 fingers) consisted of counting the fol-
lowing 5 covariables per linear millimeter: capillaries, giant
capillaries (hairpin-shaped or horseshoe-shaped, homogenously
large capillary with a diameter .50 mm), irregularly enlarged
capillaries (diameter .20 mm; morphology can be hairpin-
shaped, tortuous, or crossing once), microhemorrhages (dark
masses due to hemosiderin deposits, which can be linked to a dis-
appearing capillary), and neoangiogeneses (meandering, rami-
fied, branching, bushy, bizarre capillaries and capillaries with .2
crossings), plus a sixth covariable consisting of measuring the
maximal capillary diameter in capillaries with a diameter .50
mm (see Supplementary Materials, Investigator booklet).
To ensure optimal reliability in the assessment, staff at
all centers had been trained on the assessment of capillaroscopic
images in an interactive workshop with practical use of the capil-
laroscopy devices and were provided with a booklet containing
illustrated definitions of the capillaroscopic features (see Sup-
plementary Materials, Investigator booklet). To reflect real-
world clinical practice in this observational study, the images
were analyzed at each participating center. Picture quality was
evaluated for the first 2–3 patients at each center by 3 members
of the steering committee (MC, ALH, and VS). If the picture
quality was not optimal, further training on the correct use of
NVC was provided.
Statistical analysis. Sample size. Sample size was
based on feasibility considerations, where 350 patients enrolled
in the DU history group would provide a reasonable number of
cases (n5 150) for model building using a stagewise process to
explore risk factor associations and discrimination (30–32).
Exploratory statistical analyses were planned for 150 patients in
the no DU history group, where the number of cases was
expected to be low. Stratification was used to increase homoge-
neity within the DU history and no DU history groups, because
the factors associated with the occurrence of new DUs in the
two groups were expected to be different.
Analysis of risk factors for the occurrence of new
DUs. Covariables were described for cases and noncases using
summary statistics. Associations between the individual categorical
covariables and new DU outcomes were initially explored using chi-
square test or Fisher’s exact test, as appropriate. Summary statistics
were provided for continuous variables within the case and noncase
groups and for the differences between the 2 groups. Logistic
regression modeling was the main analytical method for examining
the associations and discriminatory ability of potential risk factors
for the occurrence of new DUs, including linear and quadratic func-
tional relationships. The strength of association between a risk fac-
tor and new DU outcome was given by the odds ratio (OR) with its
95% confidence interval (95% CI); statistical significance was given
via Wald’s chi-square test. Model calibration in the multivariable
logistic regression (MLR) analysis was assessed via the Hosmer-
Lemeshow chi-square test. The discriminatory performance of the
various risk factors (individually and combined) was given by the
receiver operating characteristic (ROC) area under the curve
(AUC) and its corresponding 95% CI.
The statistical strategy for selecting the best-performing
risk factors for the final MLR model was a stagewise process in 3
broad stages using “bundles” of covariables (33,34) (see Supple-
mentary Tables 1–6), where stage 1 is univariable logistic regres-
sion (ULR) analysis, stage 2 is MLR within-bundle analysis, and
stage 3 is MLR across-bundles analysis. The number of covari-
ables was reduced at each stage, and the best-performing covari-
ables from the bundles were carried forward to the next stage.
The non-NVC covariables with similar characteristics
(according to the domains on the case report forms) were orga-
nized into 4 bundles: bundle 1 for demographics, bundle 2 for SSc
clinical characteristics, bundle 3 for DU characteristics, and bundle
4 for other clinical characteristics. Six sub-bundles of NVC covari-
ables (bundles 5.1–5.6) were derived in various ways from the 6
assessed covariables for the 4 fingers on each hand. The NVC sub-
bundles were organized on 3 levels for building competing MLR
models: the patient, hand, and finger levels (see Supplementary
Table 5). The 1 NVC pattern qualitative covariable was used in an
alternative final model as a surrogate for the NVC quantitative
covariables. Bundle 6 was formed for statistical investigation of
interactions between covariables, which were prespecified by
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clinical consensus (see Supplementary Table 8, available online at
http://onlinelibrary.wiley.com/doi/10.1002/art.39718/abstract).
The pattern of medication use (by class) varied from one
country to another, and patients took a wide range of combina-
tions from the different medication classes. An analysis showed
that medication use within 3 months prior to and at enrollment
was associated with DU disease severity prior to and at enroll-
ment (number of DUs, by Cochran-Armitage trend test, and pre-
vious hospitalizations due to DUs, by chi-square test) (Table 3).
Specifically, DU disease severity and medication use were collin-
ear, meaning that one could be predicted from the other with
reasonable accuracy. Therefore, due to the collinearity in the
multivariable regression and the complexity of medication use
patterns across the countries, it was decided to not include medi-
cation use as a potential risk factor, but to instead include DU
disease severity in the model-building process.
Statistical criteria for selecting good-performing covari-
ables via forward stepwise selection (FSS) at the ULR stage
were the Wald’s chi-square test statistic, P, 0.15 for linear
terms, or P, 0.05 for quadratic terms. Categorical variables
with a frequency of ,20 patients were not moved forward from
ULR to MLR (see Supplementary Table 9, available online at
http://onlinelibrary.wiley.com/doi/10.1002/art.39718/abstract). In
addition to FSS, the nominal group technique was used by the
steering committee to exclude some covariables based on lack
of clinical plausibility and/or feasibility, with particular regard to
use in standard practice (see Supplementary Table 10). Statisti-
cal criteria for selecting covariables via FSS during MLR stage
2 (within-bundle) analysis were to enter if P, 0.15 and retain if
P, 0.10. At MLR stage 3 (across-bundles) analysis, statistical
criteria for selecting covariables via FSS were to enter if
P, 0.15 and retain if P, 0.05. The reduction of covariables at
each of the 3 stages resulted in the final MLR model.
Modeling within each of the NVC sub-bundles resulted
in 6 competing MLR models. In order to retain only 1 type of
NVC assessment in the final model from among the several
assessment options for the NVC (qualitative or quantitative [on
the patient, hand, and finger levels]), it was decided to carry for-
ward the sub-bundle with the highest ROC AUC into the
across-bundles stage.
Model validation. Internal validation of the final MLR
model was performed through the bootstrap method (35),
with 2,000 re-samples using the same model-building and
covariable selection procedures as for the final model.
SAS software, version 9.1.3, was used for the statistical
analysis and the reporting of clinical data.
RESULTS
Findings in the study population. DU outcome
was known for 591 of the 623 enrolled patients. Among
those 591 patients, 468 (79.2%) belonged to the DU his-
tory group (Figure 1), of whom 103 (22.0%) developed a
DU during the observation period. Of the 123 patients in
the no DU history group, only 5 (4.1%) developed a new
DU (Figure 1). As the incidence of new DUs in the no
DU history group was low, this report focuses on the DU
history group. The distribution of the total number of
patients and the number of patients who developed a new
DU (cases) were highly variable across countries and cen-
ters (see Supplementary Figure 2, available online at http://
onlinelibrary.wiley.com/doi/10.1002/art.39718/abstract).
The results of the covariable selection process for the
best-performing risk factors for new DU outcome for
each bundle at stages 1, 2, and 3 of model development
are presented in detail in Supplementary Tables 1–6.
Table 3. Medication use and relationship to DU disease severity*
Medication class
Summary statistics
P for association with
DU disease severity
No. (%) of
cases (n5 103)
No. (%) of
noncases (n5 365)
No. of DUs
(n5 468)†
Hospitalization
due to DUs (n5 468)‡
At least 1 medication class 97 (94.2) 343 (94.0) – –
Vasoactive medication
Endothelin receptor antagonists 43 (41.7)§ 113 (31.0) 0.0251 0.0856
Phosphodiesterase 5 inhibitors 15 (14.6) 31 (8.5) 0.0088 0.8604
Prostanoids, including intravenous formulation 54 (52.4)§ 140 (38.4) 0.3159 ,0.0001
Angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers
27 (26.2) 112 (30.7) 0.3283 0.5535
Calcium-channel blockers 57 (55.3) 206 (56.4) 0.1044 0.0553
Selective serotonin reuptake inhibitors 11 (10.7) 39 (10.7) 0.1935 0.0192
Nitrates 3 (2.9) 15 (4.1) 0.9737 0.7506
Statins 10 (9.7)§ 69 (18.9) 0.0568 0.1097
Other vasodilators 10 (9.7) 53 (14.5) 0.3635 0.1534
Platelet aggregation inhibitors 39 (37.9) 163 (44.7) 0.1265 0.2490
Immunosuppressants 53 (51.5)§ 139 (38.1) 0.1989 0.7551
* Includes ongoing medication use and medication use within 3 months prior to and at enrollment. DU5 digital ulcer.
† By Cochran-Armitage trend test.
‡ By chi-square test.
§ P, 0.05 versus noncases, by chi-square test and Fisher’s exact test.
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Demographic features, digital ulcers, and clini-
cal characteristics. Of the DU history group, 79.5% of
patients were female, 280 (59.8%) were classified as having
limited cutaneous SSc, and 188 (40.2%) as having diffuse
cutaneous SSc. The demographic, DU, and clinical charac-
teristics, according to DU outcome, are reported in Table 1.
The presence and number of DUs at enrollment were
significantly associated with the occurrence of new DUs
(P, 0.001), with the ORs increasing with an increasing num-
ber of DUs at enrollment. The OR of having a new DU was
2.691 (95% CI 1.507–4.803) in patients with 1 DU at enroll-
ment, 3.787 (95% CI 1.879–7.630) in those with 2 DUs, and
7.399 (95% CI 3.687–14.848) in those with$3 DUs.
The ROC AUCs for individual non-NVC covari-
ables by ULR (stage 1) had a range between 0.520 and
0.678 (Table 1). The highest ROC AUC for the non-
NVC covariables selected by MLR within-bundle (stage
2) was for the DU characteristics bundle, at 0.694 (95%
CI 0.637–0.751) (see Supplementary Tables 11–14, avail-
able online at http://onlinelibrary.wiley.com/doi/10.1002/
art.39718/abstract). Calcinosis was present in 20.4% of
cases and 18.4% of noncases. On ULR analysis, calcino-
sis was not significantly associated with the development
of new DUs (OR 1.090 [95% CI 0.637–1.866]).
The vasomodulating and immunosuppressive med-
ications taken during the 3 months prior to or at enroll-
ment and their association with DU disease severity, are
described in Table 3. During the observation period, medi-
cation use was stable for the drug classes recorded.
NVC covariables, qualitative and quantitative
measurements. Descriptive analysis of the NVC covari-
ables selected at the ULR stage and carried forward to
the MLR within-bundle analysis, are reported in Table 2
and in Supplementary Tables 5 and 6. The NVC pattern
was significantly associated with the DU outcome
(P, 0.002); the proportion of patients with a late SSc
NVC pattern was higher in the cases than in the noncases
(71.8% versus 54.0%), and the OR for a late versus nor-
mal/early SSc NVC pattern was 4.150 (95% CI 1.441–
11.950), which is consistent with previous reports (20,21).
The mean number of capillaries per millimeter was signifi-
cantly reduced in cases versus noncases regardless of the
NVC quantitative assessment type used (patient, hand, or
finger level).
The NVC covariables selected by MLR within-
bundle analysis (stage 2) are depicted in Supplementary
Tables 15 and 16 (available online at http://onlinelibrary.
wiley.com/doi/10.1002/art.39718/abstract). The NVC sub-
bundle encompassing analysis at the finger level of the
dominant hand in the 4 individual fingers (sub-bundle
5.5) had the highest ROC AUC among the 6 competing
NVC sub-bundle models (ROC AUC 0.677 [95% CI
0.614–0.740]) and was carried forward to the MLR
across-bundles analysis (stage 3). The complete list of
NVC covariables carried forward from MLR within-
bundle to MLR across-bundles analysis is presented in
Supplementary Table 17 (available online at http://
onlinelibrary.wiley.com/doi/10.1002/art.39718/abstract).
Interactions between covariables. Analysis of
the interactions bundle 6 showed that none of the 8
interaction terms were statistically significant. There-
fore, no interaction terms were carried forward to the
MLR across-bundles analysis.
Non-NVC and NVC covariables in MLR across-
bundles analysis. MLR across-bundles analysis (stage 3)
resulted in the final model with 3 risk factors: 1) the mean
number of capillaries/mm in the middle finger of the dom-
inant hand (evaluated on 2 adjacent fields in the middle of
the nailfold), with an OR of 0.838 (95% CI 0.735–0.955),
2) the number of DUs at the enrollment visit (categorized
as 0, 1, 2, or $3), with an OR for $3 DUs versus 0 DUs
at enrollment of 6.160 (95% CI 2.999–12.653), and 3) the
presence of critical digital ischemia at enrollment, with an
OR of 3.194 (95% CI 1.284–7.945) (Table 4). The ROC
AUC for the model was 0.738 (95% CI 0.681–0.795), and
the trade-off between sensitivity and specificity can be
seen in the crossover curves (see Supplementary Figure 3,
available online at http://onlinelibrary.wiley.com/doi/10.
1002/art.39718/abstract). The Hosmer-Lemeshow test
indicated that the final model did not show a significant
lack of fit (P5 0.751). Internal validation of the final
Figure 1. Flow chart showing the distribution of the study patients
and stratification of the digital ulcer (DU) outcome set. In total, 637
patients with systemic sclerosis were screened. After exclusion of
screening failures, ineligible patients, premature discontinuations, and
patients not assigned to case or noncase categories, the DU outcome
evaluable set (n5 591) was obtained. Because the variables that influ-
ence the occurrence of a new DU were thought to be different in the
DU history group (those with a history of DUs or with DUs at enroll-
ment) versus the no DU history group (those without a history of
DUs), the data analysis was stratified in the same two study arms.
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MLR model through bootstrap generated a ROC AUC of
0.633 (95% CI 0.510–0.756).
A supplementary analysis in which the NVC pat-
tern was used as the NVC covariable in the final model
yielded similar model performance, with a ROC AUC
of 0.715 (95% CI 0.658–0.771).
DISCUSSION
The CAP study was the first large, prospective,
international, multicenter study to evaluate capillaroscopic
and other clinical characteristics to determine risk factors
for the development of new DUs during a 6-month period
in patients with SSc. A very low number of cases were
reported in the no DU history group during the 6-month
observation period; therefore, risk factor analysis was per-
formed only on the DU history group. The strongest
performing risk factors for the occurrence of new DUs
identified by MLR analysis were the mean number of
capillaries per millimeter in the middle finger of the domi-
nant hand, the number of DUs at enrollment, and the
presence of critical digital ischemia at enrollment.
The characteristics of our study population were
similar to those in the European League Against Rheuma-
tism (EULAR) Scleroderma Trials and Research Group
(EUSTAR) cohort of patients with SSc (36). As expected,
it appeared that the number of DUs had a large influence
on the risk of future DUs, which is consistent with data
reported previously (37,38), and may be linked to
increased severity of SSc disease, since patients with DUs
are more likely to have an earlier onset of SSc and more
extensive skin involvement (3). There are a number of
therapies available for the prevention of DUs (32,39,40),
and it is therefore important to identify patients who are
at risk of developing DUs so that they can receive preven-
tive management.
Consistent with previous studies, the CAP study
revealed capillary density (number of capillaries/mm) as
the most robust NVC risk factor for new DUs. Of note, loss
of capillaries has been linked to an increased risk of devel-
oping SSc and may therefore predict an early diagnosis,
more severe skin involvement, and a poorer prognosis
(21,41–46). While the current study found that the capillary
density on the third digit of the dominant hand was suffi-
cient for predicting the risk of new DUs, it is still necessary
to evaluate at least 4 digits per hand for the diagnosis of SSc
in patients with Raynaud’s phenomenon. The study also
indicated that the NVC pattern may play a role in pre-
dicting DUs, confirming the results of smaller studies that
have shown that the late SSc NVC pattern is associated
with an increased risk of DUs (20,47,48). Ideally, future
studies would encompass NVC-based indices assessing
Table 4. Final multivariable logistic regression model*
Variable
Coefficient
estimate
MLR
Standard error Odds ratio (95% CI) Wald’s chi-square test P
Intercept 21.0864 0.3299 0.337 (0.177–0.644) 10.8445 0.0010
Mean no. of capillaries/mm
in middle finger of dominant hand
20.1770 0.0670 0.838 (0.735–0.955) 6.9801 0.0082
No. of DUs at enrollment
1 0.7460 0.3307 2.109 (1.103–4.032) 5.0878 0.0241
2 1.1696 0.3889 3.221 (1.503–6.902) 9.0458 0.0026
$3 1.8181 0.3672 6.160 (2.999–12.653) 24.5082 ,0.0001
Critical digital ischemia
present at enrollment
1.1613 0.4649 3.194 (1.284–7.945) 6.2388 0.0125
* The final prognostic model used 3 variables to predict the occurrence of digital ulcers (DUs) within 6 months: the mean number of capillaries/
mm in the middle finger of the dominant hand, the number of DUs at enrollment (categorized as 0, 1, 2, or $3), and the presence/absence of
critical digital ischemia (defined as prolonged, severe, persistent reduction in digital tissue perfusion without rewarming) at enrollment. The mul-
tivariable logistic regression (MLR) coefficient estimates indicate that the risk of developing a DU within 6 months increases in patients with
critical digital ischemia at enrollment, in patients with a greater number of DUs, and in patients with a lower number of capillaries/mm in the
middle finger of the dominant hand. No variable among the demographic, SSc clinical, or other clinical characteristic bundle was retained.
Receiver operating characteristic curve analysis showed an area under the curve of 0.738 (95% confidence interval [95% CI] 0.681–0.795). The
Hosmer-Lemeshow goodness-of-fit test yielded the following values: x25 5.0602, 8 df, P5 0.751. The MLR equation, based on the estimates
shown in the table, was as follows:
Probability of new DUs within 6 months 5 exp linear predictorð Þ= 1 1 exp linear predictorð Þ½ 
where the linear predictor is 21.0864 (intercept) 20.1770 multiplied by the mean number of capillaries per mm in the middle finger of the dom-
inant hand, plus either 0.7460 for the presence of 1 DU, 1.1696 for 2 DUs, or 1.8181 for $3 DUs at enrollment, plus 1.1613 for the presence of
critical digital ischemia at enrollment. Thus, a patient with 5 capillaries/mm in the middle finger of the dominant hand, plus 2 DUs at enroll-
ment, plus critical digital ischemia at enrollment has a 59% probability of developing new DUs within 6 months.
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eventual disease-modifying characteristics of treatment on
the clinical complications of SSc such as DUs (49,50).
With regard to the individual performance of each
of the final model’s 3 variables in the ULR analysis, the
number of DUs was the strongest risk factor (ROC AUC
0.678), followed by the number of capillaries/mm in the mid-
dle finger of the dominant hand (ROC AUC 0.614), and
then the presence of critical digital ischemia at enrollment
(ROC AUC 0.556). The combination of the 3 variables in
the final MLR model improved the model’s discriminatory
ability (ROC AUC 0.738). Furthermore, the relative
weights of the Wald’s chi-square values for the 3 variables
(Table 4) demonstrated that both the number of capillaries/
mm in the middle finger of the dominant hand (NVC vari-
able) and critical digital ischemia at enrollment make impor-
tant additional contributions to the number of DUs for
determining the risk of new DUs in the final MLR model.
Interestingly, whereas a 50% incidence of new
DUs in the DU history group had been assumed in the
sample size estimation of our study, in reality, there was
only a 22% incidence. The lower-than-expected incidence
of new DUs may be the result of patients already receiving
best practice standard of care for the management of their
disease at enrollment. Medication use was not restricted,
varied between countries, and was found to be associated
with DU disease severity, which is consistent with findings
from the Digital Ulcer Outcome Registry showing that
patients with chronic and/or recurrent DUs have a shorter
time to new DUs as compared with patients with no or epi-
sodic DUs (51). Therefore, medication use was not consid-
ered to be an independent variable and was not included
as a potential risk factor for new DUs.
Because the no DU history subgroup was consid-
ered exploratory, it was not possible to identify variables
that predicted DUs because of the small number of cases
in this subgroup. We had anticipated at least 20% of cases,
based on the report that 50% of patients with SSc experi-
ence DUs (1) and the fact that the first DU usually occurs
early in the disease course (3); however, we observed only
4.1% of cases of new DUs in this subgroup. This may have
2 explanations. First, the SSc population may have chan-
ged in the last few years: patients with SSc may be diag-
nosed earlier than in the past, and preventive and efficient
measures are now more widely used. Second, it might
have been beneficial to restrict patients in the no DU his-
tory group to those with a first non–Raynaud’s phenome-
non symptom within 1 year (instead of 2 years) in order to
be closer to the population described by Hachulla et al
(3), in which 43% of patients had their first DU within 1
year of their first clinical sign of SSc.
NVC has the potential to be a useful tool for moni-
toring the progression of microvascular disease associated
with SSc and for measuring the response to treatment
(52,53). It is a well-established, noninvasive technique that
allows for higher-magnification analysis compared with the
older widefield capillaroscopic method (53,54). The train-
ing needed for the device is minimal (;5 days [55]) and
the required examination time is short (;10 minutes
including image recording). An NVC apparatus is more
costly than handheld devices such as dermatoscopes, but
NVC has been shown to permit more-detailed assessments
(56) and the grading of more images (54). During patient
follow-up, detailed assessment and quantification of
abnormalities is important, and therefore, handheld tools
may not be as useful in this setting (53). Of note, capilla-
roscopy has been recently introduced as a criterion in the
ACR/EULAR classification criteria for SSc (16), thereby
increasing their sensitivity and specificity.
Overall, there are several key strengths of this
study. First is its generalizability, ensured by the broad
distribution of participating centers and patients repre-
senting current standard of care. Second is its applicabil-
ity in real-world clinical practice, owing to the broad study
population, the simplicity and ease of clinical evaluation
of the NVC, and the clinical risk factors that built the
final model. Third is its value in the management of
patients with a history or presence of DUs. The scope of
the CAP study was to determine risk factors for develop-
ing DUs by using NVC and other clinical characteristics
in routine clinical practice and health care environments,
including centers with different levels of NVC experience.
Thus, the “center” was not regarded as a potential risk
factor, which could allow generalizability of the study
findings for patients with SSc outside of the study centers.
The interrater variability of NVC assessments has been of
concern, and the capillary density has been identified as
the NVC variable with the best interrater agreement in
earlier, smaller studies (28,57). In the CAP study, inter-
rater variability was addressed by practical training and
teaching booklets that were offered to the investigators.
Despite these efforts, the ambitious intention to allow
extrapolation to the real-world setting may have intro-
duced a large amount of noise that was detrimental to
obtaining a final model with high discriminatory ability.
Limitations of this study include the fact that the
diagnosis of DUs and critical digital ischemia is not
always unequivocal (58,59), although definitions were
provided in the protocol and/or the case report form.
Investigators were not blinded to the NVC and other
clinical characteristics assessed at enrollment and may
therefore have been biased in favor of a diagnosis of a
new DU. However, this was inherent to the real-world
nature of the study, as physicians in clinical practice are
not blinded to the results of other assessments.
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Although the wide geographic spread of centers permits
generalizability, it was conducive to introducing hetero-
geneity in the data. The center effect could not be
explored in depth because of the wide distribution of
patients across a large number of centers, with a small
number of cases per center. Although it was estimated
that 150 cases would be a reasonable number for explor-
ing risk factor associations with the development of
DUs, only 103 cases were observed in this cohort and, as
such, the study was underpowered. Nevertheless, the
modeling strategy (ULR, MLR within-bundle, MLR
across-bundles analyses), together with the reduction in
the number of variables entered into the model and the
bootstrap validation demonstrated the robustness of the
variables in the final model, thereby compensating for
the lower-than-prespecified number of cases.
Laboratory biomarkers were not included in this
study, which could have helped to improve the discrimi-
natory ability of the final model. Biomarkers have previ-
ously been shown to be useful for predicting DUs (60)
and may be useful to include in future studies. Given
the nature of this real-world observational study, it was
not feasible to determine the presence of an association
between medication use and development of DUs.
Future larger studies could be designed to explore this
association by controlling for confounding factors such
as DU disease severity and the use of medications (indi-
vidually and in combination) in different countries.
In conclusion, this longitudinal, multicenter
study of almost 500 patients with SSc has shown that the
mean number of capillaries/mm on the middle finger of
the dominant hand, the number of DUs at enrollment,
and the presence of critical digital ischemia at enroll-
ment are risk factors for the development of new DUs.
The risk factors identified are simple to evaluate in the
clinic, and the real-world nature of the study allows the
results to be generalized to a wider SSc population,
thereby providing the physician with useful information
when considering a patient’s risk of future DUs.
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